Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial

Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…

AI Summary: An international Phase III trial led by UCLA reveals that giredestrant, a novel endocrine therapy, significantly reduces recurrence risk in early‐stage breast cancer compared with standard care. The robust findings promise to shift hormonal treatment paradigms—even if skeptics may raise a wry eyebrow at yet “another” incremental advance in a crowded field.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Brian Lawenda: Visual Decision Aid To Simplify Breast Cancer Treatment Choices for Women 65+

5 months / oncodaily

Runcie Chidebe: Fatima Cardoso Presents the Advanced Breast Cancer Global Decade Report 2015–2025

5 months / oncodaily

Adrian Lee: Global Research Focus on Lobular Breast Cancer at SABCS 2025

5 months / oncodaily

SABCS 2025: Tissue-Free ctDNA Surveillance Anticipates Relapse in High-Risk Early TNBC

5 months / oncodaily

Clinical characteristics and prognostic impact of HER2 low expression in breast cancer subtypes from a Brazilian real-world cohort

5 months / nature

Aydah AlAwadhi: Survivorship in Young Women with Breast Cancer is Complex